

Contact: Hariharan Subramanian
PancreaSolve, Inc.
Phone: (617) 553-1015
701 Concord Avenue
Cambridge, MA 02138
info@pancreasolve.com
www.pancreasolve.com

PancreaSolve™

PRESS RELEASE

PancreaSolve, Inc. gears for the critical in vitro validation of the in silico models at MD Anderson Cancer Center

Cambridge, November 18, 2016: In a milestone step, PancreaSolve, Inc. is gearing for the in vitro validation of the pancreatic cancer stroma in silico models. The in vitro studies will be conducted at MD Anderson Cancer Center.

"We are excited to start in vitro validation step for the pancreatic cancer stroma models as it will be a critical in validating the in silico models. We have completed the experimental design for the in vitro studies and finalized the parameters that will be compared from the in silico and in vitro analyses. The in vitro study will be supervised by Dr. Sunil Krishnan at MD Anderson Cancer Center," said Dr. Prabhakar Deonikar, Director of Research at PancreaSolve.

"The in vitro validation of the pancreatic cancer stroma in silico models provides an important milestone. Once the validation is done, the increase in confidence level for the in silico models will enable us to start the drug discovery process by testing the efficacy of various drug combinations on the models first, thereby accelerating the drug discovery process," said Dr. Shiva Ayyadurai, Chief Executive Officer of PancreaSolve.

PancreaSolve is headquartered in Cambridge, MA. PancreaSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics for pancreatic cancer.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.